Global Idiopathic Hypersomnia Treatment Market
Overview:
Idiopathic hypersomnia is a neurological condition that affects the sleeping pattern of an individual. It affects the everyday routine of a person and also causes behavioral changes. This disease mostly begins during adolescence and develops throughout adulthood from weeks to months. Patients suffering from idiopathic hypersomnia find it difficult to stay awake during the day and suffer from excessive sleepiness during the day. Moreover, patients can fall asleep during inappropriate times which results in interference with daily activities. However, no drug has been approved for idiopathic hypersomnia, sodium oxybate can be used for providing symptomatic relief to the patients.
To Get More Business Strategies Request Sample Copy of This Research Report:) @ https://www.coherentmarketinsights.com/insight/request-sample/4306
Impact of Covid-19:
The pandemic has affected several industries globally, leading to the disruptions in supply of raw materials required for manufacturing drugs. This disruption in supply chain is caused due to forced quarantine, shortage of raw materials and labor. Traveling constraints, social distancing measures and quarantine have also led to the disruptions in transportation of raw materials and also resulted in decline of business. Moreover, key players in the market are focusing on research and developmental activities due to increasing incidences of COVID-19, for development of new products for battling COVID-19. Clinical trials of drugs for idiopathic hypersomnia have been stopped in the beginning of 2020, thus, impacting the development and research in the sector.
Drivers:
Rising incidences of idiopathic hypersomnia and increasing awareness are estimated to propel growth of the global idiopathic hypersomnia treatment market during forecast period. For instance, the Hypersomnia Foundation, Inc., joined the GivingTuesday Campaign in order to increase funding and awareness regarding idiopathic hypersomnia.
Moreover, product pipeline for the treatment of idiopathic hypersomnia is also anticipated to fuel growth of the global idiopathic hypersomnia treatment market over forecast period. For instance, Lynn Marie Trotti, Emory University and the American Academy of Sleep Medicine, partnered up for initiating the study of phase 2 Modafinil Versus Amphetamines, which is used for treating idiopathic hypersomnia and type 2 narcolepsy.
For More Information or Query or Customization before Buying, Visit at – https://www.coherentmarketinsights.com/insight/talk-to-analyst/4306
Key Takeaways:
- The global idiopathic hypersomnia treatment market is anticipated to exhibit a CAGR of 8.7% over the forecast period, due to increasing incidences of lifestyle diseases like depression, anxiety along with that the rise in the diagnosis rate with the help of modern technologies. For instance, a study was published in the iMedPub Journals stated that in 2016, in France, more than 6% of the population was suffering from anxiety.
- The stimulant medications segment, among drug class is estimated to witness robust growth in the global idiopathic hypersomnia treatment market during the forecast period, due to increasing demand for stimulant medications, as these drugs show higher efficacy in the treatment of hypersomnia. For instance, several approved stimulants like Methylphenidate and dextroamphetamine are present in the market for treating sleeping disorders like narcolepsy.
- The hospital pharmacies segment, amongst the terms of distribution of the global idiopathic hypersomnia treatment market is expected to witness growth during the forecast period, owing to increasing number of admissions in hospitals for the treatment of panic disorders, anxiety and a few rare diseases. For instance, the data by United Kingdom National Health Service mentions that there has been a rise in hospital admission for anxiety and stress by 28% in the last decade in the United Kingdom.
- North America is expected to witness robust growth in the global idiopathic hypersomnia treatment market during the forecast period, due to rise in awareness campaigns related to rare diseases like idiopathic hypersomnia, increasing healthcare expenditure, favorable reimbursement scenario and clinical trials. For instance, in March 2015, the analysis of the Hypersomnia Foundation’s International Patient Registry at CoRDS was done for individuals suffering from Kleine-Levin syndrome, narcolepsy and idiopathic hypersomnia.
Key players:
Key players active in the global idiopathic hypersomnia treatment market are Drive DeVilbiss Healthcare LLC, Teva Pharmaceutical Industries Ltd., Fisher & Paykel Healthcare Limited, Jazz Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Theranexus, , Avadel Pharmaceuticals, Plc, Merck & Co. Inc and BIOPROJET.
Grab the Offer and Get UpTo 30% Discount on This Research Report 2022-2028 @ https://www.coherentmarketinsights.com/promo/buynow/4306
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- CKD Stages Treatment Options
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Market Trends
- Recent Product Launch/Approvals
- Cost of Treatment
- Regulatory Scenario
- PEST Analysis
- Mergers, Acquisitions, and Partnerships
- Epidemiology
- Reimbursement Scenario (Medicare Part D Spending)
- Global Idiopathic Hypersomnia Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- Supply and Demand Analysis
- Research and Development
- Government Initiatives
- Global Idiopathic Hypersomnia Treatment Market, By Drug Class, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Stimulant Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Non-stimulant wake-promoting Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Sodium Oxybate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Idiopathic Hypersomnia Treatment Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/idiopathic-hypersomnia-treatment-market-3569
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837